155 related articles for article (PubMed ID: 12023519)
21. Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice.
Baskfield CY; Martin BR; Wiley JL
J Pharmacol Exp Ther; 2004 Apr; 309(1):86-91. PubMed ID: 14718593
[TBL] [Abstract][Full Text] [Related]
22. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
23. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
25. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum.
Wang X; Horswill JG; Whalley BJ; Stephens GJ
Mol Pharmacol; 2011 Apr; 79(4):758-67. PubMed ID: 21189269
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
27. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration.
Sim-Selley LJ; Schechter NS; Rorrer WK; Dalton GD; Hernandez J; Martin BR; Selley DE
Mol Pharmacol; 2006 Sep; 70(3):986-96. PubMed ID: 16760363
[TBL] [Abstract][Full Text] [Related]
28. The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific.
Niyuhire F; Varvel SA; Thorpe AJ; Stokes RJ; Wiley JL; Lichtman AH
Psychopharmacology (Berl); 2007 Apr; 191(2):223-31. PubMed ID: 17211653
[TBL] [Abstract][Full Text] [Related]
29. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats.
Lichtman AH; Dimen KR; Martin BR
Psychopharmacology (Berl); 1995 Jun; 119(3):282-90. PubMed ID: 7675962
[TBL] [Abstract][Full Text] [Related]
30. The endogenous cannabinoid system controls extinction of aversive memories.
Marsicano G; Wotjak CT; Azad SC; Bisogno T; Rammes G; Cascio MG; Hermann H; Tang J; Hofmann C; Zieglgänsberger W; Di Marzo V; Lutz B
Nature; 2002 Aug; 418(6897):530-4. PubMed ID: 12152079
[TBL] [Abstract][Full Text] [Related]
31. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
Darmani NA
J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
33. Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
González S; Bisogno T; Wenger T; Manzanares J; Milone A; Berrendero F; Di Marzo V; Ramos JA; Fernández-Ruiz JJ
Biochem Biophys Res Commun; 2000 Apr; 270(1):260-6. PubMed ID: 10733937
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoids and memory: animal studies.
Castellano C; Rossi-Arnaud C; Cestari V; Costanzi M
Curr Drug Targets CNS Neurol Disord; 2003 Dec; 2(6):389-402. PubMed ID: 14683467
[TBL] [Abstract][Full Text] [Related]
35. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze.
Takahashi RN; Pamplona FA; Fernandes MS
Neurosci Lett; 2005 Jun; 380(3):270-5. PubMed ID: 15862900
[TBL] [Abstract][Full Text] [Related]
36. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.
Buckley NE; McCoy KL; Mezey E; Bonner T; Zimmer A; Felder CC; Glass M; Zimmer A
Eur J Pharmacol; 2000 May; 396(2-3):141-9. PubMed ID: 10822068
[TBL] [Abstract][Full Text] [Related]
38. A role for endocannabinoids in indomethacin-induced spinal antinociception.
Gühring H; Hamza M; Sergejeva M; Ates M; Kotalla CE; Ledent C; Brune K
Eur J Pharmacol; 2002 Nov; 454(2-3):153-63. PubMed ID: 12421642
[TBL] [Abstract][Full Text] [Related]
39. Memory impairment following combined exposure to delta(9)-tetrahydrocannabinol and ethanol in rats.
Ciccocioppo R; Antonelli L; Biondini M; Perfumi M; Pompei P; Massi M
Eur J Pharmacol; 2002 Aug; 449(3):245-52. PubMed ID: 12167466
[TBL] [Abstract][Full Text] [Related]
40. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists.
Wiley JL; Beletskaya ID; Ng EW; Dai Z; Crocker PJ; Mahadevan A; Razdan RK; Martin BR
J Pharmacol Exp Ther; 2002 May; 301(2):679-89. PubMed ID: 11961073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
